CCTx-001 clinical trials

An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

This study is testing a new drug called CCTx-001 for adults with a type of blood cancer called Acute Myeloid Leukaemia (AML) that has come back or not responded to previous treatments. It aims to see if CCTx-001 is safe, well-tolerated, and effective.